StockData
Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc (ENTA) stock

ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 2/3018% above fair value
$10.99−0.21 (-1.87%)

Close on Nov 13, 2026Market cap $320.09MP/E –Yield –

Earnings

Enanta Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 16, 2026
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$14.40M
-21.3% on a year earlier
EPS, Q3 FY2026
-$0.67
-$0.85 a year earlier
Latest guidance
Raised
May 6, 2024 · 2 items

Quarterly results

Revenue and earnings per share from each of Enanta Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Sep 30, 2026Nov 16, 2026Expected––––
Q3 FY2026ended Jun 30, 2026Aug 10, 2026during market hours$14.40M-21.3%-$0.67Release
Q2 FY2026ended Mar 31, 2026May 11, 2026during market hours$17.20M–-$0.45Release
Q1 FY2026ended Dec 31, 2025Feb 9, 2026during market hours$18.60M+9.4%-$0.42Release
Q4 FY2025ended Sep 30, 2025Nov 17, 2025during market hours$15.10M+3.4%-$0.87Release
Q3 FY2025ended Jun 30, 2025Aug 11, 2025during market hours$18.30M+1.7%-$0.85Release
Q1 FY2025ended Dec 31, 2024Feb 10, 2025during market hours$17.00M-5.6%-$1.05Release
Q4 FY2024ended Sep 30, 2024Nov 25, 2024during market hours$14.60M-22.8%-$1.36Release
Q3 FY2024ended Jun 30, 2024Aug 5, 2024during market hours$18.00M-4.8%-$1.07Release
Q2 FY2024ended Mar 31, 2024May 6, 2024during market hours$17.10M-3.9%-$1.47Release
Q1 FY2024ended Dec 31, 2023Feb 7, 2024during market hours$18.00M-23.7%-$1.58Release
Q4 FY2023ended Sep 30, 2023Nov 20, 2023during market hours$18.90M-6.9%-$1.33Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Enanta Pharmaceuticals guided for has been reported

Guidance history

Every forecast Enanta Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
May 6, 2024General and administrative expenseFY2024$50.00M – $60.00MLowered
May 6, 2024Research and development expenseFY2024$125.00M – $145.00MRaised
Nov 20, 2023General and Administrative ExpenseFY2024$45.00M – $50.00MLowered
Nov 20, 2023Research and Development ExpenseFY2024$100.00M – $120.00MNew
Aug 7, 2023General and Administrative ExpenseFY2023$50.00M – $55.00MLowered
Aug 7, 2023Research and Development ExpenseFY2023$165.00M – $175.00MRaised
Nov 21, 2022General and Administrative ExpenseFY2023$46.00M – $52.00MLowered
Nov 21, 2022Research and Development ExpenseFY2023$210.00M – $230.00MNew
Nov 22, 2021General and Administrative ExpenseFY2022$35.00M – $41.00MLowered
Nov 22, 2021Research and Development ExpenseFY2022$150.00M – $170.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Enanta Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Results
  3. Update
  4. Update
  5. Results
  6. Results
  7. Results
  8. Update
  9. Update
  10. Update
  11. Results
  12. Results
  13. Results
  14. Update
  15. Update

See a number that looks wrong?